The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 17, 2023

Filed:

Oct. 15, 2021
Applicant:

Thiogenesis Therapeutics, Inc., San Diego, CA (US);

Inventors:

Vincent P. Stanton, Jr., Belmont, MA (US);

Patrice P. Rioux, San Diego, CA (US);

Assignee:

Thiogenesis Therapeutics, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/16 (2006.01); A61K 31/145 (2006.01); A61K 9/50 (2006.01); A61K 9/00 (2006.01); C07C 323/52 (2006.01); C07C 323/25 (2006.01); C07F 9/6561 (2006.01); A61K 9/28 (2006.01); A61K 31/6615 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
A61K 31/16 (2013.01); A61K 9/0065 (2013.01); A61K 9/0095 (2013.01); A61K 9/2846 (2013.01); A61K 9/2866 (2013.01); A61K 9/5073 (2013.01); A61K 9/5084 (2013.01); A61K 31/145 (2013.01); A61K 31/6615 (2013.01); C07C 323/25 (2013.01); C07C 323/52 (2013.01); C07F 9/65616 (2013.01); G01N 33/5023 (2013.01);
Abstract

The invention features compositions, methods, and kits containing (i) one or more cysteamine precursor compounds convertible to cysteamine in vivo, and (ii) optionally agents to enhance that conversion, formulated to produce a spectrum of pharmacokinetic profiles of cysteamine that can be tailored to individual patients and diseases. The invention also features varying modes of administration of the therapeutic substances in the treatment of cystinosis and other cysteamine sensitive disorders. In particular, formulations combining active ingredient(s) with pharmaceutical excipients that permit sustained cysteamine plasma concentrations are featured.


Find Patent Forward Citations

Loading…